These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30973654)

  • 21. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
    To KK; Tong CW; Wu M; Cho WC
    World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
    Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
    Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
    Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Genes Related to Clinicopathological Characteristics and Prognosis of Patients with Colorectal Cancer.
    Gao X; Yang J
    DNA Cell Biol; 2020 Apr; 39(4):690-699. PubMed ID: 32027181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long noncoding RNA KCNQ1OT1 promotes colorectal carcinogenesis by enhancing aerobic glycolysis via hexokinase-2.
    Chen C; Wei M; Wang C; Sun D; Liu P; Zhong X; Yu W
    Aging (Albany NY); 2020 Jun; 12(12):11685-11697. PubMed ID: 32564010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KCNQ1OT1/miR-217/ZEB1 feedback loop facilitates cell migration and epithelial-mesenchymal transition in colorectal cancer.
    Bian Y; Gao G; Zhang Q; Qian H; Yu L; Yao N; Qian J; Liu B; Qian X
    Cancer Biol Ther; 2019; 20(6):886-896. PubMed ID: 30794031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients.
    Ke J; Liu XH; Jiang XF; He Z; Xiao J; Zheng B; Chen YF; Cai ZR; Zheng XB; Zou YF; Lan P; Wu XJ; Gao F
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e62-e70. PubMed ID: 32863096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
    Li L; Ni BB; Zhong QH; Liu YH; Zhang MH; Zhang KP; Chen DC; Wang L
    Future Oncol; 2017 Jul; 13(17):1473-1492. PubMed ID: 28685592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.
    Li X; Jonnagaddala J; Yang S; Zhang H; Xu XS
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1955-1963. PubMed ID: 35332389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
    Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
    Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
    Williams DS; Mouradov D; Browne C; Palmieri M; Elliott MJ; Nightingale R; Fang CG; Li R; Mariadason JM; Faragher I; Jones IT; Churilov L; Tebbutt NC; Gibbs P; Sieber OM
    Mod Pathol; 2020 Mar; 33(3):483-495. PubMed ID: 31471586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
    Li W; Qiu T; Guo L; Ying J
    Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.